219 related articles for article (PubMed ID: 29415334)
1. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
2. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
[TBL] [Abstract][Full Text] [Related]
3. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
Pilgrim H; Lloyd-Jones M; Rees A
Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
6. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
7. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
[TBL] [Abstract][Full Text] [Related]
8. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
[TBL] [Abstract][Full Text] [Related]
9. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
Szczepura A; Osipenko L; Freeman K
BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
[TBL] [Abstract][Full Text] [Related]
10. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
[TBL] [Abstract][Full Text] [Related]
11. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis.
Yang H; Llewellyn A; Walker R; Harden M; Saramago P; Griffin S; Simmonds M
BMC Med; 2019 Feb; 17(1):37. PubMed ID: 30760268
[TBL] [Abstract][Full Text] [Related]
12. Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews.
Ryczek E; White J; Carolan-Rees G
Transfus Med; 2020 Aug; 30(4):287-294. PubMed ID: 32447792
[TBL] [Abstract][Full Text] [Related]
13. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
[TBL] [Abstract][Full Text] [Related]
15. Antenatal
Clausen FB
Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
[TBL] [Abstract][Full Text] [Related]
16. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Hawk AF; Chang EY; Shields SM; Simpson KN
Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
[TBL] [Abstract][Full Text] [Related]
17. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
[TBL] [Abstract][Full Text] [Related]
18. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
Kent J; Farrell AM; Soothill P
BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
[TBL] [Abstract][Full Text] [Related]
19. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
